Neurocrine Biosciences
NBIX
326 hedge funds and large institutions have $7.8B invested in Neurocrine Biosciences in 2019 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 142 increasing their positions, 98 reducing their positions, and 49 closing their positions.
45% more repeat investments, than reductions
Existing positions increased: 142 | Existing positions reduced: 98
40% more call options, than puts
Call options by funds: $108M | Put options by funds: $77.1M
20% more capital invested
Capital invested by funds: $6.51B → $7.8B (+$1.29B)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
8% less first-time investments, than exits
New positions opened: 45 | Existing positions closed: 49
2% less funds holding
Funds holding: 331 → 326 (-5)
2.79% less ownership
Funds ownership: 100.24% → 97.45% (-2.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$112M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$75.4M |
| 3 |
HM
HealthCor Management
New York
|
+$62.5M |
| 4 |
DCP
DSM Capital Partners
Palm Beach Gardens,
Florida
|
+$58.2M |
| 5 |
Millennium Management
New York
|
+$45.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$216M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$116M |
| 3 |
CAM
Close Asset Management
London,
United Kingdom
|
-$86.9M |
| 4 |
PA
Perceptive Advisors
New York
|
-$71M |
| 5 |
TCM
TimesSquare Capital Management
New York
|
-$62M |
NBIX Hedge Fund Activity: Q1 2019 in Review
326 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q1 2019, worth a combined $7.8B — up 20% from $6.51B a quarter earlier.
Sellers outnumbered buyers: 49 funds closed out of NBIX and 45 opened new positions — a net loss of 4 holders — while 98 trimmed existing stakes and 142 added.
The largest buyer was OrbiMed, adding an estimated $112M. The largest seller was Fidelity Investments, cutting an estimated $216M.
- 326 institutional investors held Neurocrine Biosciences (NBIX) as of Q1 2019, down from 331 in Q4 2018.
- Funds reported $7.8B of Neurocrine Biosciences stock for Q1 2019, up 20% quarter-over-quarter.
- 45 funds opened new Neurocrine Biosciences positions in Q1 2019 and 49 closed out, a net change of -4 holders.
- The largest Neurocrine Biosciences buyer in Q1 2019 was OrbiMed, an estimated $112M added.
- The largest Neurocrine Biosciences seller in Q1 2019 was Fidelity Investments, an estimated $216M sold.
Based on aggregated 13F filings for Q1 2019.